Reata Pharmaceuticals (RETA) PT Raised to $180 at Cantor Fitzgerald on Favorable MOXIe Data
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan raised the price target on Reata Pharmaceuticals (NASDAQ: RETA) to $180.00 (from $125.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
